DWP05195, DWP418_Daewoong Pharmaceutical Co., Ltd.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Novel Neuropathic Pain Therapeutics : DWP05195, Oncolytic Adenovirus Cancer Gene Therapy : DWP418
Send an Inquiry
RE:
Participants
You

1. Novel Neuropathic Pain Therapeutics: DWP05195


 


Indication: Neuropathic Pain


 


u  Caused by primary lesion or dysfunction of the nervous system


u  No effective pharmacological solution      


 


Candidate Profile


 


u  Potent pharmacological effect on Neuropathic Pain (TRPV1 antagonist)


u  No clinical adverse effect


u  Favorable PK profile


u  Ease of synthesis


u  Solid patent profiles


 


Development Status 


 


u  Clinical Phase II


u  Completed by 4Q 2011


 


2.  Oncolytic Adenovirus Cancer Gene Therapy: DWP418


 


Indication: Refractory Solid Tumors


 


Candidate Profile


 


u  Oncolytic adenovirus (defined as the killing of tumor cells by virus infection, replication)


ü  Cancer-specific replication by novel modified hTERT promoter


ü  Viral spreading effect of Relaxin


u  Therapeutic potency shown in both in vitro & in vivo studies


ü  Tumor growth was suppressed dose-dependently with a single dose injection


ü  Tumor growth was suppressed according to the injection frequency


u  Reduced side effects due to cancer-specific proliferation


 


Development Status 


 


u  Clinical Phase I


u  Completed by 1Q 2011

FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
GOVERNMENT INSTITUTE

Opportunity Contact